

**1. AMENDMENT AND LISTING OF CLAIMS:**

*This listing of claims will replace all prior versions and listings of claims in the application:*

1. (Previously Presented) A recombinant adeno-associated viral vector comprising at least a first nucleic acid segment encoding a biologically-active mammalian Factor VII peptide, polypeptide or protein operably linked to at least a first promoter capable of expressing said segment in a mammalian host cell transformed with said vector.
- 2-7. (Canceled)
8. (Previously Presented) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII peptide, polypeptide or protein that comprises the sequence of any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.
9. (Original) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active human Factor VII peptide, polypeptide or protein.
- 10.-15. (Canceled)
16. (Previously Presented) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment comprises the nucleotide sequence of any one of SEQ

ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11,  
or SEQ ID NO:13.

17.-26. (Canceled)

27. (Original) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 85% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.
28. (Original) The recombinant adeno-associated viral vector of claim 27, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 90% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.
29. (Original) The recombinant adeno-associated viral vector of claim 28, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 95% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.

30. (Original) The recombinant adeno-associated viral vector of claim 29, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 98% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.
31. (Original) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 85% identical to the amino acid sequence of SEQ ID NO:2.
32. (Original) The recombinant adeno-associated viral vector of claim 31, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 88% identical to the amino acid sequence of SEQ ID NO:2.
33. (Original) The recombinant adeno-associated viral vector of claim 32, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 91% identical to the amino acid sequence of SEQ ID NO:2.
34. (Original) The recombinant adeno-associated viral vector of claim 33, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 94% identical to the amino acid sequence of SEQ ID NO:2.

35. (Original) The recombinant adeno-associated viral vector of claim 34, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 97% identical to the amino acid sequence of SEQ ID NO:2.
36. (Original) The recombinant adeno-associated viral vector of claim 1, comprised within an adeno-associated viral particle.
37. (Canceled)
38. (Original) The recombinant adeno-associated viral vector of claim 1, comprised within an isolated mammalian host cell.
- 39.-40. (Canceled)
41. (Currently Amended) An isolated host cell comprising: ~~(a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; or (c) the plurality of viral particles of claim 40.~~
- 42.-44. (Canceled)
45. (Currently Amended) A composition comprising: (a) the recombinant adeno-associated viral vector of claim 1; ~~(b) the virion of claim 39; (c) the plurality of viral particles of claim 40;~~ or ~~(b)~~ the isolated host cell of claim 41.

46.-55. (Canceled)

56. (Withdrawn) A method for providing an animal a biologically-active Factor VII peptide or polypeptide, said method comprising administering to said mammal: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40; (c) the host cell of claim 41; or (d) the composition of claim 45, in an amount and for a time sufficient to provide said mammal with an effective amount of said biologically-active Factor VII peptide or polypeptide.

57. (Canceled)

58. (Withdrawn) A method for treating or ameliorating the symptoms of a Factor VII polypeptide defect, deficiency or dysfunction in a mammal, said method comprising administering to said mammal: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40; (c) the host cell of claim 41; or (d) the composition of claim 45, in an amount and for a time sufficient to treat or ameliorate the symptoms of said defect, deficiency or dysfunction in said mammal.

59. (Withdrawn) The method of claim 58, wherein said mammal has, is at risk for developing, or is diagnosed with hemophilia, a clotting deficiency, or a bleeding disorder.

60. (Withdrawn) A method for treating or ameliorating the symptoms of hemophilia in a mammal, said method comprising administering to said mammal: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40; (c) the host cell of claim 41; or (d) the composition of claim 45, in an amount and for a time sufficient to treat or ameliorate the symptoms of hemophilia in said mammal.

61.-64. (Canceled)

65. (New) A recombinant adeno-associated viral vector comprising at least a first nucleic acid segment that encodes a biologically-active mammalian Factor VII polypeptide comprising the amino acid sequence of SEQ ID NO:2, operably linked to at least a first promoter capable of expressing said segment in a mammalian host cell transformed with said vector.

66. (New) A recombinant adeno-associated viral vector comprising at least a first nucleic acid segment that comprises the polynucleotide sequence of SEQ ID NO:1, operably linked to at least a first promoter capable of expressing said segment in a mammalian host cell transformed with said vector.